T0	Interventions 10 57	unfractionated and low-molecular-weight heparin
T1	Interventions 323 394	unfractionated (UFH) and low-molecular-weight (LMWH enoxaparin) heparin
T2	Interventions 640 809	to either enoxaparin (n = 10) or UFH (n = 11) anticoagulation and followed prospectively for 12 weeks before crossing over to the alternate therapy for further 12 weeks.
T3	Interventions 810 921	The OPG, RANKL, and vWF levels were measured at T0, T10, and T180 of HD session after each period of evaluation
T4	Interventions 968 977	under UFH
T5	Interventions 1126 1141	both enoxaparin
T6	Interventions 1495 1501	during
T7	Interventions 1581 1597	under enoxaparin
T8	Interventions 1644 1660	under enoxaparin
T9	Interventions 1762 1779	Impact of heparin